The Public Health Agency of Canada (PHAC) will be purchasing IMVAMUNE smallpox vaccine at a value of approximately USD 56 million.
The non-replicating smallpox vaccine is also approved for use against monkeypox in Canada as the only territory other than the USA.
Deliveries of vaccines under this five-year contract are expected to occur from 2023. Hence this contract will have no impact on the Company’s financial guidance for 2022.
Secure contracts with other countries
In parallel, Bavarian Nordic continues to secure contracts with other countries, including Denmark, but also countries outside Europe, to supply the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness, it states.
Photo of Paul Chaplin, CEO, Bavarian Nordic